Newsfeeds - Spark Newswire

1 minute read

Halozyme To Acquire Antares Pharma For $5.60/Share In Cash; Transaction Values Antares At $960M

Today, 8:34 AM

SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") and Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares") today

ATRS

1 minute read

M&A
News

Wall Street Journal Reported Halozyme Therapeutics Nears Deal to Buy Antares Pharma for $5.60/Share in Cash

By Charles Gross

Today, 8:34 AM

https://www.wsj.com/articles/halozyme-therapeutics-nears-deal-to-buy-antares-pharma-11649840401#:~:text=Halozyme%20would%20pay%20%245.60%20a,value%20of%20roughly%20%24640%20million.

ATRS

1 minute read

Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties

By Vandana Singh

Today, 8:34 AM

Johnson & Johnson’s (NYSE:JNJ) Janssen has won an arbitration against Genmab A/S (NASDAQ:GMAB) on two matters related to their licensing pact for…

GMAB

2 minute read

Legal
News

Genmab Announced the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement

By Charles Gross

Today, 8:34 AM

Genmab A/S (Nasdaq: GMAB) announced today an award in the binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab. The arbitral tribunal issued an award on April 7, 2022, deciding both issues in favor of Janssen.

GMAB

1 minute read

Halozyme, Chugai Ink $185M ENHANZE Technology Licensing Pact

By Vandana Singh

Today, 8:34 AM

Halozyme Therapeutics Inc (NASDAQ: HALO) has

HALO

1 minute read

Halozyme’s Q4 Earnings Beat Consensus Despite Lower Product Sales Hit Topline Growth

By Vandana Singh

Today, 8:34 AM

Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q4 r

HALO

1 minute read

Earnings

Halozyme Therapeutics: Q4 Earnings Insights

By Benzinga Insights

Today, 8:34 AM

Halozyme Therapeutics (NASDAQ:HALO) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

HALO

1 minute read

Halozyme Therapeutics Q4 EPS $0.42 Beats $0.41 Estimate, Sales $102.00M Beat $100.32M Estimate

By Benzinga Newsdesk

Today, 8:34 AM

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.41 by 2.44 percent. This is a 16 percent decrease over earnings of $0.50 per share from

HALO

11 minute read

Earnings Scheduled For February 22, 2022

By Benzinga Insights

Today, 8:34 AM

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million.

4 minute read

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow

By Shanthi Rexaline

Today, 8:34 AM

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.

ABCL